Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study

Hajo Grundmann; Corinna Glasner; Barbara Albiger; Laurent Poirel; *European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group; Ana Kaftandzieva; Elena  Trajkovska Dokic

doi:10.1016/S1473-3099(16)30257-2

Occurrence of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in the European survey of carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective, multinational study

Journal

The Lancet Infectious Diseases

Date Issued

2017-02

Author(s)

Hajo Grundmann

Corinna Glasner

Barbara Albiger

Laurent Poirel

*European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) Working Group

DOI

10.1016/S1473-3099(16)30257-2

Abstract

Background Gaps in the diagnostic capacity and heterogeneity of national surveillance and reporting standards in Europe make it diffi cult to contain carbapenemase-producing Enterobacteriaceae. We report the development of a consistent sampling framework and the results of the fi rst structured survey on the occurrence of carbapenemase-producing Klebsiella pneumoniaeandEscherichia coli in European hospitals.Methods National expert laboratories recruited hospitals with diagnostic capacities, who collected the fi rst ten carbapenem non-susceptible clinical isolates of K pneumoniaeorE coli and ten susceptible same-species comparator isolates and pertinent patient and hospital information. Isolates and data were relayed back to national expert laboratories, which made laboratory-substantiated information available for central analysis. Findings Between Nov 1, 2013, and April 30, 2014,455 sentinel hospitals in 36 countries submitted 2703 clinical isolates (2301 [85%] K pneumoniae and 402 (15%) E coli). 850 (37%) of 2301 K pneumoniae samples and 77 (19%) of 402 E colisamples were carbapenemase (KPC, NDM, OXA-48-like, or VIM) producers. The ratio of K pneumoniae to E coli was 11:1. 1·3 patients per 10 000 hospital admissions had positive clinical specimens. Prevalence diff ered greatly, with the highest rates in Mediterranean and Balkan countries. Carbapenemase-producing K pneumoniae isolates showed high resistance to last-line antibiotics. Interpretation This initiative shows an encouraging commitment by all participants, and suggests that challenges in the establishment of a continent-wide enhanced sentinel surveillance for carbapenemase-producing Entero-bacteriaeceae can be overcome. Strengthening infection control eff orts in hospitals is crucial for controlling spread through local and national health care networks.

File(s)

Name

Lancet-2017-Article.pdf

Size

1.35 MB

Format

Adobe PDF

Checksum

(MD5):b44ff42b8f7ab52ecfa38f5afd356f6c